

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ELI LILLY AND COMPANY  
Petitioner

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH  
Patent Owner

---

IPR2018-01426  
Patent No. 9,890,211

---

**PETITIONER'S EXHIBIT LIST AS OF AUGUST 8, 2018**

Petitioner's Exhibit List  
U.S. Patent No. 9,890,211

<b>Exhibit</b>	<b>Description</b>
Exhibit 1001	U.S. Patent No. 9,890,211
Exhibit 1002	Reserved
Exhibit 1003	Reserved
Exhibit 1004	Reserved
Exhibit 1005	Reserved
Exhibit 1006	Reserved
Exhibit 1007	Reserved
Exhibit 1008	Reserved
Exhibit 1009	Reserved
Exhibit 1010	Reserved
Exhibit 1011	Reserved
Exhibit 1012	Declaration of Andrew Charles, M.D. (U.S. Patent No. 9,890,211)
Exhibit 1013	Declaration of Alain P. Vasserot (U.S. Patent No. 9,890,211)
Exhibit 1014	Reserved
Exhibit 1015	Reserved
Exhibit 1016	Reserved
Exhibit 1017	Reserved
Exhibit 1018	Reserved
Exhibit 1019	Teva's U.S. Provisional Application No. 60/736,623
Exhibit 1020	Teva's PCT Application No. WO 2007/054809

Exhibit	Description
Exhibit 1021	Tan et al., "Demonstration of the Neurotransmitter Role of Calcitonin Gene-Related Peptides (CGRP) by Immunoblockade with Anti-CGRP Monoclonal Antibodies," <i>Br. J. Pharmacol.</i> (1994) 111: 703-710
Exhibit 1022	Tan et al., "Calcitonin Gene-Related Peptide as an Endogenous Vasodilator: Immunoblockade Studies in vivo with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody and Its Fab' Fragment," <i>Clinical Sci.</i> (1995) 89: 565-573
Exhibit 1023	Queen et al., U.S. Patent No. 6,180,370
Exhibit 1024	Doods et al., "Pharmacological Profile of BIBN4096BS, the First Selective Small Molecule CGRP Antagonist," <i>Br. J. Pharmacol.</i> (2000) 129: 420-423
Exhibit 1025	Olesen et al., "Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine," <i>N. Engl. J. Med.</i> (2004) 350: 1104-1110
Exhibit 1026	Sveinsson, International Publication No. WO 2004/014351
Exhibit 1027	Salmon et al., U.S. Patent Application Publication No. US 2002/0162125
Exhibit 1028	De Lacharriere et al., U.S. Patent No. 6,344,438
Exhibit 1029	Olesen et al., "S26 CGRP Antagonism as a New Therapeutic Principle in Acute Migraine," <i>Neuropeptides</i> (2004) 38: 110-131
Exhibit 1030	Arndt et al., "CGRP Antagonism — A Valid New Concept for the Treatment of Migraine Pain," <i>Neuropeptides</i> (2004) 38: 110-131
Exhibit 1031	Arulmani et al., "Calcitonin Gene-related Peptide and Its Role in Migraine Pathophysiology," <i>Eur. J. Pharmacol.</i> (2004) 143: 315-330

Exhibit	Description
Exhibit 1032	Frobert et al., "A Sensitive Sandwich Enzyme Immunoassay for Calcitonin Gene-Related Peptide (CGRP): Characterization and Application," <i>Peptides</i> (1999) 20: 275-284
Exhibit 1033	Wong et al., "Monoclonal Antibody to Rat $\alpha$ -CGRP: Production, Characterization, and in vivo Immunoneutralization Activity," <i>Hybridoma</i> (1993) 12: 93-106
Exhibit 1034	Rist et al., "From Micromolar to Nanomolar Affinity: A Systematic Approach to Identify the Binding Site of CGRP at the Human Calcitonin Gene-Related Peptide 1 Receptor," <i>J. Med. Chem.</i> (1998) 41: 117-123
Exhibit 1035	Edvinsson and Hargreaves, <i>The Headaches</i> 289-299 (3rd ed. 2006)
Exhibit 1036	Reserved
Exhibit 1037	Reserved
Exhibit 1038	Mason et al., "Release of the Predicted Calcitonin Gene-Related Peptide from Cultured Rat Trigeminal Ganglion Cells," <i>Nature</i> (1984) 308: 653-655
Exhibit 1039	Brain et al., "Calcitonin Gene-Related Peptide is a Potent Vasodilator," <i>Nature</i> (1985) 313: 54-56
Exhibit 1040	Arulmozhi et al., "Migraine: Current Concepts and Emerging Therapies," <i>Vascular Pharmacol.</i> (2005) 43: 176-187
Exhibit 1041	Durham, "CGRP-Receptor Antagonists - A Fresh Approach to Migraine Therapy?" <i>N. Engl. Med.</i> (2004) 250(11): 1073-1075
Exhibit 1042	Iovino et al., "Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS, the First Selective Small Molecule Calcitonin Gene-related Peptide Receptor Antagonist, Following Single Intravenous Administration in Healthy Volunteers," <i>Cephalalgia</i> (2004) 24: 645-656

Petitioner's Exhibit List  
U.S. Patent No. 9,890,211

Exhibit	Description
Exhibit 1043	Goadsby et al., "Vasoactive Peptide Release in the Extracerebral Circulation of Humans During Migraine Headache," <i>Annals of Neurology</i> (1990) 28(2): 183-187
Exhibit 1044	Goadsby and Edvinsson, "The Trigeminovascular System and Migraine: Studies Characterizing Cerebrovascular and Neuropeptide Changes Seen in Humans and Cats," <i>Annals of Neurology</i> (1993) 33(1): 48-56
Exhibit 1045	Juhasz et al., "NO-induced Migraine Attack: Strong Increase in Plasma Calcitonin Gene-Related Peptide (CGRP) Concentration and Negative Correlation with Platelet Serotonin Release," <i>Pain</i> (2003) 106: 461-470
Exhibit 1046	Goadsby and Edvinsson, "Human in vivo Evidence for Trigeminovascular Activation in Cluster Headache: Neuropeptide Changes and Effects of Acute Attacks Therapies," <i>Brain</i> (1994) 117: 427-434
Exhibit 1047	Lassen et al., "CGRP May Play a Causative Role in Migraine," <i>Cephalalgia</i> (2002) 22: 54-61
Exhibit 1048	Louis et al., "Antibodies to Calcitonin-Gene Related Peptide Reduce Inflammation Induced by Topical Mustard Oil But Not that Due to Carrageenin in the Rat," <i>Neuroscience Letters</i> (1989) 102: 257-260
Exhibit 1049	Dockray et al., "Immunoneutralization Studies with Calcitonin Gene-Related Peptide," <i>Annals of N.Y. Acad. Scis.</i> (1992) 258-267
Exhibit 1050	Louis et al., "The Role of Substance P and Calcitonin Gene-Related Peptide in Neurogenic Plasma Extravasation and Vasodilation in the Rat," <i>Neuroscience</i> (1989) 32(3): 581-586
Exhibit 1051	Sigma-Aldrich, Biochemicals & Reagents for Life Science Research 350-352 (2004)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.